William Looney
Editor-in-Chief
wlooney@advanstar.com
William Looney is the Editor in Chief of Pharmaceutical Executive magazine, a monthly print and weekly on-line publication focused on the “c suite” concerns of senior managers in the biopharmaceutical industry. In addition to editorial content, he is responsible for supporting the magazine through related educational media activities and serving as a thought leader in contacts between the magazine and a wide variety of organizations.
Prior to joining Pharmaceutical Executive in August 2009, Mr. Looney served for 11 years as Senior Director at Pfizer, Inc. where he managed the company’s public policy issue development, positioning and advocacy activities outside the US. In that capacity, he worked closely with the academic and think tank community, coordinated Pfizer CEO relationships with the World Economic Forum, Japan’s Nikkei Management Forum and other policy groups, and chaired committees of key biopharma trade associations, including PhRMA and the IFPMA.
Earlier in his career, he served as an internal communications manager and speech writer at Warner Lambert Company in both the US and in Europe. He also was senior editor for the Economist Intelligent Unit, where he was responsible for consumer issues and management practices in Europe.
He has also been a consultant to the organization for Economic Cooperation and Development [OECD], and is the author of numerous research papers and studies focused on the relationships between product and process innovation and public health.
In March 2011 he was honored by American Business Media with a Neal Award for 'Best Commentary' for his monthly 'From the Editor' columns.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.